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Rett syndrome (Rtt) is a severe neurological disorder usually caused by mutations in the MECP2 gene. 
Since the MECP2 gene is located on the X chromosome, X chromosome inactivation (Xci) could play a 
role in the wide range of phenotypic variation of Rtt patients; however, classical methylation-based 
protocols to evaluate Xci could not determine whether the preferentially inactivated X chromosome 
carried the mutant or the wild-type allele. Therefore, we developed an allele-specific methylation-based 
assay to evaluate methylation at the loci of several recurrent MECP2 mutations. We analyzed the Xci 
patterns in the blood of 174 RTT patients, but we did not find a clear correlation between XCI and the 
clinical presentation. We also compared Xci in blood and brain cortex samples of two patients and found 
differences between XCI patterns in these tissues. However, RTT mainly being a neurological disease 
complicates the establishment of a correlation between the Xci in blood and the clinical presentation 
of the patients. furthermore, we analyzed MECP2 transcript levels and found differences from the 
expected levels according to XCI. Many factors other than XCI could affect the RTT phenotype, which 
in combination could influence the clinical presentation of RTT patients to a greater extent than slight 
variations in the Xci pattern.
Rett syndrome (RTT, OMIM #312750) is a severe neurodevelopmental disorder characterized by a period of nor-
mal development until 6-18 months of age followed by a regression of neurological traits. RTT features include 
compromised brain functions, severe mental retardation, epilepsy, regression of purposeful hand use and lan-
guage, breathing disturbances, gait apraxia and repetitive stereotyped hand movements1–3. RTT has an incidence 
of 1:10,000–20,000 live births and affects mainly young females4, being the second most common cause of severe 
mental retardation in females after Down syndrome.
The association of RTT with mutations in methyl-CpG binding protein 2 (MECP2; Xq28; OMIM *300005) 
gene was recognized in 19992. Since then, more than 800 different mutations in MECP2 have been identified 
in more than 95% of patients with classic RTT5,6. There are also some atypical RTT variants, such as the early 
onset seizure variant and the congenital variant, which have been associated with mutations in cyclin-dependent 
kinase-like 5 (CDKL5; Xp22; OMIM *300203) and forkhead box protein G1 (FOXG1; 14q12; OMIM *164874), 
respectively7,8. However, the vast majority of RTT patients have a de novo mutation in MECP2, and there are 
8 mutation hotpots with recurrent mutations (p.Thr158Met, p.Arg255*, p.Arg168*, p.Arg306Cys, p.Arg294*, 
p.Arg270*, p.Arg133Cys and p.Arg106Trp), which are responsible for over 60% of all RTT cases9,10.
Increasing experience has shown that RTT patients present a large degree of phenotypic variation2. Patients 
with truncating mutations in MECP2 tend to show a more severe phenotype than those with missense mutations4, 
and there are also phenotypical presentation differences between patients with the same mutation11–13.
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These clinical differences have been attributed, at least in part, to X chromosome inactivation (XCI). Through 
the XCI process, mammalian female cells inactivate one of the two X chromosomes to compensate for gene 
dosage. XCI is a stochastic process that takes place in the initial stages of the embryogenesis, causing a mosaic 
expression of X-linked genes in the adult organism3,14,15. Since MECP2 is located on the X chromosome, the 
severity of RTT could be theoretically regulated by XCI, showing a more severe phenotype as more cells express 
the mutated MECP214.
Some cases of healthy carriers of RTT-causing mutations with highly skewed XCI patterns have been doc-
umented14,16,17, as have cases of RTT patients with milder symptoms who also presented a skewed XCI pat-
tern13,17,18. However, in most XCI studies in RTT, the phase of the two X chromosomes was not determined, so the 
XCI pattern could only be classified as either skewed or random. Therefore, no evidence of whether the preferen-
tially inactivated chromosome was the mutant or the wild-type (WT) could be obtained.
We have developed an allele-specific methylation-based assay to evaluate methylation on the loci of several 
recurrent MECP2 mutations, allowing for evaluation of the XCI pattern while taking into account which is the 
mutant and which is the wild-type allele. We compared the results from the classical androgen receptor assay for 
evaluating X chromosome inactivation (XCI-AR) with the allele-specific X chromosome inactivation (XCI-AS) 
assay we developed. We also compared all XCI results with a score of clinical severity of the clinical presentation 
of RTT to determine if we could correlate the XCI pattern with milder or more severe forms of RTT. Our cohort 
included 221 RTT patients with several recurrent mutations and two deletions in MECP2, for whom we could 
evaluate XCI patterns in blood. Moreover, we also assessed XCI in brain samples of two patients and compared 
the XCI status to blood to determine if it could be used as an accurate predictor. Finally, we measured MECP2 
RNA levels in brain samples to determine whether they correlated with the XCI pattern detected.
Results
Allele-specific X chromosome inactivation and XCI skewing in blood samples. For each patient, 
we performed an XCI-AR and the corresponding XCI-AS when blood samples were available (174/221 patients), 
and we also calculated the global score of the clinical presentation when clinical data were available (181/221 
patients). The reference values for considering an XCI pattern as skewed in the literature are usually established at 
an 80:20 ratio14,19, so we also used that threshold to allow the comparison of our results with previous studies. The 
entire list of XCI results and clinical scores for all patients can be found in Supplementary Table S1.
The overall tendency of our cohort was to have random XCI. However, 9.8% of our patients showed a skewed 
XCI pattern (80:20 or higher; Table 1), which is similar to what was found in other studies13,20. No patients with p. 
R152R, p.T158M or p. P225R mutations showed skewed XCI patterns in either XCI-AR or XCI-AS.
When we applied the 80:20 skewing threshold, 17 out of 174 patients presented a skewed XCI pattern accord-
ing to at least one of the two XCI assays performed (Table 2). We compared these patients’ clinical severity scores 
with the average clinical score of RTT patients with the same mutation. We found that, when the clinical score 
was available, in the majority of cases this value was included in the interval of µ ± σ (central 68% of individuals 
in a normal distribution) of the patients with the same mutation.
There were only two patients who had a clinical score lower than the interval µ-σ for their mutation (P107 and 
P145, Table 2, in bold). In the case of patient P107, the preferentially inactivated allele was the WT allele, while 
in the case of patient P145 the mutant allele was inactivated. The results from patient P145 seem to be consistent 
with the theory that when the chromosome that harbors the MECP2 mutation is preferentially inactivated, the 
clinical presentation of RTT may be milder.
Allele-specific X chromosome inactivation and XCI skewing in brain samples. We also performed 
XCI-AR and XCI-AS assays in samples of several brain regions of two patients with the c.763C > T mutation 
(Table 3). The XCI-AS assay was useful for assessing the XCI pattern in both patients, but especially in patient 
P119, since in this case, the polymorphism in the AR locus was noninformative for the XCI-AR assay.
Mutation
Type of 
mutation
MeCP2 
region
Number of patients 
with skewed XCI
% of patients with 
skewed XCI
c.455C > G (p.P152R) Missense MBD 0/6 0%
c.473C > T (p.T158M) Missense MBD 0/33 0%
c.502C > T (p.R168X) Nonsense IDR 5/29 17.2%
c.674C > G (p.P255R) Missense TRD 0/2 0%
c.763C > T (p.R255X) Nonsense TRD 4/36 11.1%
c.806delG (p.G269fs) Frameshift TRD-NLS 1/11 9.1%
c.808C > T (p.R270X) Nonsense TRD-NLS 4/20 20%
c.880C > T (p.R294X) Nonsense TRD 1/20 5%
c.916C > T (p.R306C) Missense TRD 1/15 6.7%
Large deletions Deletion Exons 3-4 1/2 50%
All — — 17/174 9.8%
Table 1. Proportion of patients per mutation with a skewed XCI pattern according to at least one of the two 
techniques used for assessing XCI (XCI-AR and XCI-AS).
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Although no samples showed skewed XCI by either assay, there was no clear homogeneity among blood and 
brain samples. Some samples, such as the frontal cortex or the white matter sample of patient P109, showed an 
XCI pattern closer to the skewing threshold than other regions, such as the cerebellum, of the same patient. In 
patient P119, the vast majority of samples were close to the random XCI pattern, but the temporal cortex sample 
showed an XCI pattern closer to the skewing threshold.
Brain RnA analysis. Finally, we analyzed frontal and occipital cortex RNA samples. We performed RT-PCR 
to obtain cDNA samples so that we could perform Sanger sequencing to check if we could detect the presence of 
one allele over the other (Fig. 1).
In cDNA samples from patient P109, the T allele (mutated allele) was overrepresented, while in samples from 
patient P119, the C allele (WT allele) was overrepresented. However, both patients presented a severe form of 
RTT, with clinical scores of 20 and 19, respectively.
The cDNA analysis was not conclusive since Sanger sequencing is not the best technique for quantifying the 
RNA of each allele. However, the sequencing analysis seemed to indicate that one allele was more frequently pres-
ent than the other, although the XCI assay results showed inactivation patterns that did not reach the threshold 
for classifying the XCI pattern as skewed in any of the two patients and regions.
We later confirmed our findings in the frontal cortex samples by qRT-PCR, a more suitable technique for 
quantifying RNA levels (Fig. 2a,b). We found that in samples from patient P109, the mutated allele was overex-
pressed, while in samples from patients P119, the WT allele was overexpressed.
Discussion
The XCI-AS assay allowed us to describe the XCI patterns of patients previously classified as noninformative by 
the classical XCI-AR assay and to identify which MECP2 allele (mutated or WT) was preferentially inactivated in 
cases of skewed XCI pattern.
Differences between the XCI patterns obtained by both techniques can be explained because in each tech-
nique, the methylation status is only analyzed at a single locus, and the methylation of a single cytosine residue 
may not be representative of the inactivation status of the entire X chromosome21,22. Different studies have shown 
Patient Number XCI-AR
XCI-AS
Global ScoreWT Mut
Patients with c.502C > T (p.Arg168*) mutation X = 13.12 (SD = 3.361)
P47 n.i. 81.5 18.5 13
P60 84:16 28 72 16
P68 75:25 15.5 84.5 NA
P70 85:15 35 65 NA
P74 81:19 55.5 44.5 NA
Patients with c.763C > T (p.Arg255*) mutation X = 15.21 (SD = 3.213)
P83 85:15 57 43 NA
P84 87:13 55.5 44.5 13
P85 80:20 28 72 14
P107 87:13 68 32 11
Patients with c.806delG (p.Gly269fs) mutation X = 14.29 (SD = 4.112)
P139 82:18 58 42 NA
Patients with c.808C > T (p.Arg270*) mutation X = 14.69 (SD = 3.846)
P143 97:3 16 84 18
P144 84:16 21 79 NA
P145 81:19 30 70 9
P146 80:20 73 27 13
Patients with c.880C > T (p.Arg255*) mutation X = 10.46 (SD = 2.993)
P191 89:11 49 51 NA
Patients with c.916C > T (p.Arg306Cys) mutation X = 11.18 (SD = 3.065)
P195 89:11 59.5 40.5 9
Patients with deletions in MECP2
P220 88:12 6.73 93.27 NA
Table 2. Data of patients with skewed XCI according to at least one of the two assays. The XCI-AR column 
shows the results of the AR XCI assay (percentage of inactivation of each allele). The XCI-AS WT and Mut 
columns show the results of the allele-specific XCI assay (percentage of inactivation of each allele, mean of two 
replicates n = 2 or three replicates n = 3 in the cases of the deletions). The Global Score column shows the 
average (X) score and its standard deviation (SD) in brackets for the patients of our cohort with each mutation. 
Bold formatting indicates patients with a clinical score lower than the interval µ-σ for the average clinical score 
of their mutation. n.i. = polymorphism noninformative for the assay. NA = clinical data not available.
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that when methylation in several loci of the X chromosome is assessed, different ratios of XCI can be obtained, 
with up to 27% of variation21,22. Therefore, the use of several loci for characterizing XCI would indicate the true 
XCI pattern more consistently21.
Sample XCI-AR
XCI-AS
WT Mut
Patient 109 (Clinical score = 20)
Frontal Cortex 65:35 26 74
Occipital Cortex 58:42 59 41
Parietal Cortex 64:36 40 60
Temporal Cortex 60:40 32 68
White matter 59:41 23 77
Brain stem 59:41 31 69
Striatum 61:39 51 49
Cerebellum 55:45 43 57
Blood 73:27 64 36
Patient 119 (Clinical score = 19)
Frontal Cortex n.i. 48 52
Occipital Cortex n.i. NA NA
Parietal Cortex n.i. 56 44
Temporal Cortex n.i. 73 27
White matter n.i. 46 54
Brain stem n.i. 38 62
Striatum n.i. 50 50
Cerebellum n.i. 50 50
Blood n.i. 34 66
Table 3. Data of patients P109 and P119 with the c.763C > T mutation. The XCI-AR column shows the 
results of the AR XCI assay (percentage of inactivation of each allele). The XCI-AS WT and Mut columns 
show the results of the allele-specific XCI assay (percentage of inactivation of each allele). n.i. = polymorphism 
noninformative for the assay. NA = data not available.
Figure 1. Brain RNA Sanger Sequencing. cDNA analysis of brain samples. Electropherograms obtained from 
Sanger sequencing of frontal and occipital cortex cDNA samples. Blue peaks correspond to the C allele (WT), 
while red peaks correspond to the T allele (mutated), and the red box highlights the locus of the c.763C > T 
mutation in heterozygosis. Inactivation ratios are shown as inactivation WT:inactivation Mut.
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Gathering data from both XCI assays performed with samples of 174 patients, we found that 9.8% of patients 
had skewed XCI patterns (80:20 XCI ratio or higher). Other studies have found either similar results13,20 or a 
considerably higher incidence of skewing, up to 43%, among RTT patients23. Some authors claim that most of 
the patients who meet the diagnostic criteria for RTT have a random XCI pattern, while those with skewed XCI 
patterns may not meet all the criteria and therefore are not included in some RTT studies18.
However, the percentage of patients in our cohort with skewed XCI patterns varied among different types of 
mutations. Mutations that produce a truncated protein result in a more severe phenotype than missense muta-
tions23, and skewed XCI patterns were more common in RTT patients with deletions and nonsense mutations 
than in those with missense mutations. This could be due to a protective effect related to the severity of the muta-
tion. It is possible that mutations producing a less functional, truncated protein (deletions and nonsense muta-
tions) cause cells to preferentially inactivate the X chromosome harboring the mutation. It has been shown that 
skewed XCI can be caused by a selective advantage of cells with a particular active X chromosome proliferating 
faster than cells where the other X chromosome is active15,24,25. This type of skewing has been described in up to 
50% of familial cases of X-linked mental retardation disorders26.
This skewed proliferation could be the case for patient P220 (Table 2), who had a large deletion in MECP2 
and showed a skewed XCI pattern (88:12) by the XCI-AR assay. In this patient, the XCI-AS assay confirmed an 
extremely skewed XCI pattern and that the preferentially inactivated allele was the mutated allele at a ratio of 93:7. 
We also found this tendency in several patients with p.Arg168* (P60, P68, P70; Table 2) p.Arg255* (P85; Table 2) 
and p.Arg270* (P143, P144, P145; Table 2) mutations. However, there were other patients with these same muta-
tions with skewed XCI according to the XCI-AR assay who showed a preferential inactivation of the WT allele 
when the XCI-AS assay was performed, such as P146 (Table 2). Patient P47 (Table 2), who was noninformative 
for the XCI-AR assay, also showed a preferential inactivation of the WT allele at a ratio of 81:19 when the XCI-AS 
assay was performed. These last patients do not support the abovementioned hypothesis.
We found no substantial correlation between the XCI patterns in blood and the clinical presentation of RTT 
following the scale of evaluation of the RTT phenotype by Monrós, et al.27 (data not shown). We did not observe 
consistent increases or decreases in the clinical score of RTT patients with a preferential inactivation of the WT 
or mutated alleles in blood samples.
It has been published that XCI patterns can vary among different tissues22,28. Indeed, we compared the XCI 
patterns of blood and brain samples of the same patient, and they did not show homogeneous XCI patterns. 
Although they were small, there was also a slight difference in the XCI patterns between different brain regions 
of the same patient.
Moreover, it has been shown that blood is especially prone to XCI skewing29 because of the proliferation of 
different clones of lymphocytes under different conditions22,29. In fact, blood XCI patterns have shown variations 
at different time points in different studies14. For two of the patients included in the study (P9 and P199; Table S5), 
we compared two different blood samples from two different extractions. Both patients showed some differences 
in the results of the XCI assays in the two extraction samples.
The lack of a direct correlation between the XCI patterns in blood and the clinical presentation of RTT could 
be explained by different reasons. First, we observed that the XCI patterns in blood and different regions of the 
brain are not necessarily homogeneous. Therefore, if RTT symptoms are caused mainly by the lack of MECP2 
function in the brain, it is expected that the severity of the phenotype will be more related to the XCI pattern in 
the brain than to the XCI pattern in the blood.
Moreover, there are many other factors that can influence the presentation of the RTT phenotype, such as 
other polymorphisms and genetic variants, the expression levels of other genes and environmental conditions4. 
Figure 2. Brain RNA qRT-PCR analysis and comparison with XCI-AS assay results. (a) cDNA analysis of brain 
samples. The results obtained by qRT-PCR of frontal cortex RNA samples (% of expression of each allele). The 
discontinuous line indicates 50% of the expression of each allele (each allele is equally present in the sample). 
(b) Comparison of XCI and qRT-PCR data from patients P109 and P119 with the c.763C > T mutation. Data are 
shown as % of activation of each X chromosome (% Active) and % RNA expression measured by qRT-PCR.
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It is likely that the combination and addition of these additional factors can influence the phenotype to a greater 
extent than only the XCI pattern in the brain.
RTT symptoms arise from either a partial or a complete loss of function of MECP2 in neurons13,30. RTT 
affects mainly females, partly because a complete loss of function of MECP2 in males is so damaging that it can 
cause death in the first months of life or even before birth. The severity of the male phenotype points towards a 
dose-dependent mechanism of action of MECP2, where the expression of the mutant MECP2 in a high propor-
tion of cells causes the RTT phenotype13,31. It is possible that in females, slight deviations from random 50:50 
XCI ratios do not cause sufficient changes in the levels of the mutant MECP2 in the brain to be translated into a 
different phenotype.
However, it is possible that in more extreme cases, the effect is more remarkable. This could be similar to the 
case of female carriers of the MECP2 duplication who show an extremely skewed XCI pattern with the mutant 
chromosome inactivated in most of their cells. In these cases, where a greater number of cells have inactivated 
the mutant chromosome, the effects of the XCI pattern are more important and cause the carrier of the MECP2 
duplication not to present the MECP2 duplication syndrome. The same phenomenon could occur with patho-
genic mutations in MECP2. If there is an extremely skewed XCI pattern in the brain, where a greater number of 
cells express the WT copy of MECP2, a threshold of MECP2 function could be reached, and the RTT phenotype 
would therefore not be expressed. In some familial cases of RTT, it has been observed that a healthy mother with 
extremely skewed XCI can be a carrier of a pathogenic mutation responsible for causing RTT in her offspring16–18, 
although she remains asymptomatic. Some authors have claimed that these familial cases of RTT are only pos-
sible due to the presence of two coincident traits: RTT and the trait for skewed XCI, which would be genetically 
determined14,16.
The differences between the XCI patterns measured and the levels of each allele observed in Sanger sequenc-
ing and qRT-PCR could be due to RNA degradation, both in the postmortem interval and during life due to the 
nonsense-mediated mRNA decay (NMD) pathway, which could degrade mutant mRNA because of its potential 
to be translated into a truncated protein.
However, brain RNA levels of each allele seemed to show discrepancies with the XCI patterns identified in 
our XCI assays. Some authors have noticed discordances between the XCI pattern according to the XCI-AR assay 
and the quantification of the AR gene expression32. These discrepancies suggest, first, that the methylation assay 
may not always be representative of XCI and, second, that gene transcript levels may be regulated by more factors 
than XCI.
The difference between the XCI pattern and the final RNA levels of each allele suggests that the levels of 
MECP2 are not directly determined by the XCI pattern and that there could be mechanisms other than XCI 
involved in regulating MECP2 transcript levels. Consistent with what we have discussed, there might be other 
genes involved in regulating MECP2 transcription and/or RNA degradation, causing changes in the final levels of 
functional MECP210. Therefore, XCI may not necessarily be determining the severity of the clinical presentation 
of RTT, which would be more related to the levels of functional MECP2 in the brain30,31.
Nevertheless, it is important to keep in mind that we are measuring MECP2 transcript levels from brain bulk 
RNA. Since different neuronal types have showed diverse transcriptional profiles in several studies33, the levels 
of the MECP2 transcripts we measured do not necessarily reflect these transcript’s levels in neurons relevant for 
RTT pathophysiology.
Although one patient showed higher levels of the MECP2 mutant transcript than the other, the clinical sever-
ity scores of both patients were not dissimilar (20 vs 19). This score similarity supports the hypothesis that slight 
deviations from a 1:1 ratio of each allele produce little to no change in the RTT phenotype. It is possible that more 
consistent differences would be noticeable if one allele was more prevalent than the other, such as in asympto-
matic carriers with an XCI pattern close to the 100:0 ratio.
In conclusion, our results show that the relationship between XCI and the severity of the RTT phenotype is 
not straightforward. Factors other than XCI can influence MECP2 transcript levels, and presumably many addi-
tional factors, such as genetic polymorphisms and the expression of other genes, may influence the final clinical 
presentation of RTT. Therefore, probably only extremely skewed XCI patterns affecting neurons can be correlated 
with milder forms of RTT or asymptomatic carriers.
Materials and Methods
Sample material. The study cohort consisted of 221 RTT patients with one of the 9 following recurrent 
mutations in the MECP2 gene: c.455C > G-p.Pro152Arg (6 patients), c.473C > T-p.Thr158Met (36 patients), 
c.502C > T-p.Arg168* (38 patients), c.674C > G-p.Pro225Arg (2 patients), c.763C > T-p.Arg255* (47 patients), 
c.806delG-p.G269fs (13 patients), c.808C > T-p.Arg270* (31 patients), c.880C > T-p.Arg294* (21 patients) and 
c.916C > T-p.Arg306Cys (25 patients); and 2 patients with a large deletion in MECP2.
Samples of blood genomic DNA (gDNA) were obtained from peripheral blood leukocytes. Samples of brain 
gDNA were obtained postmortem from several brain regions (frontal, occipital, temporal and parietal cortex; 
white matter, brain stem, striatum and cerebellum) of two patients with c.763C > T mutation. RNA was also 
obtained from the frontal and occipital cortices of such patients. DNA samples were isolated using the saline 
extraction kit PUREGENE® DNA Isolation Kit of Gentra Systems®, and brain RNA samples were extracted using 
TRIzol™ Reagent from Invitrogen™.
ethical approval and informed consent. The study was approved by the ethical committees of Hospital 
Sant Joan de Déu, CEIC: Comitè d’Ètica d’Investigació Clínica- Fundació Sant Joan de Déu (internal code: PIC-
101-15). Written informed consent from the legal guardians of the patients was obtained in accordance with the 
corresponding ethical protocols to perform the genetic studies, and tissue samples from patients and controls 
were obtained according to the Helsinki Declaration of 1964, as revised in 200134.
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HpaII and HinfI digestion. Digestion of gDNA samples was performed with one of the 
methylation-sensitive restriction enzymes HpaII or HinfI (New England BioLabs® Inc.), depending on the pres-
ence of the relevant enzyme target sequences near the studied loci. In the AR, c.455C > G, c.473C > T, c.502C > T, 
c.674C > G, c.763C > T, c.806delG, c.808C > T, c.880C > T, c.916C > T and deletion 2 (NM_004992.3: 
c.887_10015 + 18460del) loci assays HpaII was used, while in the deletion 1 (NM_004992.3: c.27-10677_1192del) 
locus assay HinfI was used. A total volume of 500 ng of gDNA was digested with 0.5 μL of enzyme in a 25 μL reac-
tion volume in CutSmart 1x Buffer (New England Biolabs® Inc.). Digestions were incubated at 37 °C for 20 min-
utes followed by another 20 minutes at 80 °C for enzyme inactivation, as established in the enzyme protocol.
PCR amplification and fragment analysis. A pair of primers with the sequences described in Allen, et 
al.35 was used to amplify the AR polymorphic locus. Allele-specific primers were designed for each MECP2 recur-
rent mutation included in the study. Primer design was carried out following the recommendations in Liu, et al.36. 
For the deletion assays, a forward primer was designed inside the deletion locus and another primer immediately 
after the deletion; they were both amplified with a reverse primer outside the deleted region. All primers used 
were designed using Primer3web version 4.1.037,38, and they are shown together with PCR conditions for each 
pair in Supplementary Tables S2, S3 and S4. One primer of each pair was FAM-labeled at the 5′ end.
PCR amplification was performed using the resulting DNA after the digestion and nondigestion of each sam-
ple. PCR products were analyzed on a 3500 Genetic Analyzer (Applied Biosystems®) using GeneScan™ – 500 
LIZ® Size Standard of Applied Biosystems® as an internal size standard and Peak Scanner Software v1.0. The X 
chromosome inactivation ratios were calculated as described elsewhere35.
Brain RnA analysis. RT-PCR was performed with frontal and occipital cortex RNA of two patients with 
the c.763C > T mutation, following the recommendations provided with the SuperScript™ III First-Strand 
Synthesis SuperMix for qRT-PCR from Invitrogen™. Subsequently, Sanger sequencing of the cDNA obtained in 
the RT-PCR reaction was performed. qPCR was performed in a QuantStudio™ 6 Flex Real-Time PCR System 
(Applied Biosystems™) with TaqMan™ Gene Expression Master Mix (Applied Biosystems™) and specific 
TaqMan™ MGB probes to amplify the mutant and the wild-type alleles. qPCR data were analyzed using the 
comparative Ct method. Primers and probes were designed using Primer3web version 4.1.036,37, and they are 
listed in Supplementary Table S5.
patient phenotype evaluation and correlation analysis. When clinical data were available (181/221 
patients), the RTT phenotype was evaluated, and a score was assigned following the scale of evaluation of the RTT 
phenotype published by Monrós, et al.27.
The linear correlation between the inactivation patterns of the WT allele and the global score of each patient 
was evaluated using statistical methods that are based on Ordinary Least Squares (OLS) regression models, 
grouping patients with the same mutation.
Data Availability
All data from this article is available in the Supplementary Data.
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